Pimecrolimus 1% cream in non-specific inflammatory recurrent balanitis

Dermatology

Volumn 215, Issue 3, 2007, Pages 209-212

  Georgala, S ^a   Gregoriou, S ^a   Georgala, C ^a   Papaioannou, D ^b   Befon, A ^a   Kalogeromitros, D ^a   Rigopoulos, D ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Errikos Dinan Hospital   (Greece)

Author keywords

Balanoposthitis; Non specific balanitis; Pimecrolimus

Indexed keywords

PIMECROLIMUS; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BALANITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; PENIS GLANS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYMPTOM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BALANITIS; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; EMOLLIENTS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME;

EID: 34548480904     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106578     Document Type: Article

References (11)

1. English JC, Laws RA, Keough GC, et al: Dermatoses of the glans penis and prepuce. J Am Acad Dermatol 1997;37:1-17.
2. Fornasa CV, Calabro A, Miglietta A, et al: Mild balanoposthitis. Genitourin Med 1994;70:345-346.
3. Birley HD, Walker MM, Luzzi GA, et al: Clinical features and management of recurrent balanitis; association with atopy and genital washing. Genitourin Med 1993;69:400-403.
4. Hultsch T, Kapp A, Spergel J: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:174-187.
5. Hafner C, Hohenleutner U, Babilas P, Landthaler M, Vogt T: Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006;213:163-165.
6. Simon D, Lübbe J, Wüthrich B, Wiesner A, Weber MM, Laffitte E, Anliker MD, Schöni MH, Braathen LR, Schmid-Grendelmeier P, Gilgen Bobalj N, Schneider D: Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice: analysis of a Swiss cohort. Dermatology 2006;213:313-318.
7. Schurmeyer-Horst F, Luger TA, Böhm M: Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosi-form hand and foot eczema. Dermatology 2007;214:99-100.
8. Alessi E, Coggi A, Gianotti R: Review of 120 biopsies performed on the balanopreputial sac. Dermatology 2004;208:120-124.
9. Wollina U, Hansel G, Koch A, Abdel-Naser MB: Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin Pharmacother 2006;7:1967-1975.
10. Hafner C, Hohenleutner U, Babilas P, Landthaler M, Vogt T: Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006;213:163-165.
11. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, Schultz JC, Katz HI, McCormick CL, Parneix-Spake A: Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007;57:257-264.